Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5449]

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging...

Dr Natalia Neparidze - Yale School of Medicine, New Haven, USA

Transoral surgery and neck dissection with deintensified risk-based post...

Dr Barbara Burtness - Yale School of Medicine, New Haven, USA

Transoral surgery and neck dissection with deintensified risk-based post-operative management increases efficacy in oropharynx cancer ( Dr Barbara Burtness - Yale School of Medicine, New Haven, USA )

Osimertinib success in locally advanced EGFR-mutated NSCLC

Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA

Osimertinib success in locally advanced EGFR-mutated NSCLC ( Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA )

Adjuvant avelumab versus control does not significantly improve DFS but does...

Prof Pier Conte - University of Padova, Padova, Italy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )

Adagrasib improves on docetaxel in previously treated NSCLC

Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado

Adagrasib improves on docetaxel in previously treated NSCLC ( Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado )

Maintenance systemic therapy versus local consolidative therapy plus...

Dr Puneeth Iyengar - Memorial Sloan Kettering Cancer Center, New York, USA

Maintenance systemic therapy versus local consolidative therapy plus maintenance systemic therapy for NSCLC ( Dr Puneeth Iyengar - Memorial Sloan Kettering Cancer Center, New York, USA )

Manageable safety profile with early efficacy of Tec-DR in NDMM

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond...

Dr Dejan Juric - Massachusetts General Hospital, Boston, USA

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer ( Dr Dejan Juric - Massachusetts General Hospital, Boston, USA )

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive...

Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer ( Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy )

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan...

Dr Jane Lowe Meisel - Winship Canter Institute, Atlanta, USA

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer ( Dr Jane Lowe Meisel - Winship Canter Institute, Atlanta, USA )

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible...

Dr Paula Rodríguez-Otero - Clinica Universidad de Navarra, Pamplona, Spain

Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM: MRD analysis ( Dr Paula Rodríguez-Otero - Clinica Universidad de Navarra, Pamplona, Spain )

More from ecancer